Understanding Your Risks
Most cases of breast cancer
occur in women between the ages of 30 and 80 and about 80% of those cases
affect women age 50 and older. So the primary risk factor for breast
cancer is simply being a woman, followed by increasing age.
Other risk factors that have
been identified, include genetic links to breast cancer. But, it is unclear
how many women who are genetically predisposed to having breast cancer
ever actually develop the disease. And in other instances, people
who seem to have none of the risk factors -- such as men -- develop
breast cancer. Women account for 99 percent of breast cancer cases; men
account for nearly 1 percent.
Listed below are risk factors
associated with breast cancer. Keep in mind though that these risk factors
are just "factors." And having one or more of these risk factors does not
mean
that you will necessarily
develop breast cancer, just that you are at higher risk of developing
breast cancer than someone who does not have any of these factors.
-
Age: Both the numbers
and the seriousness of breast cancer incidence increase with age. Almost
80% of new cases of breast cancer detected each year are among women over
the age of 50.
-
Race: Caucasian women
are more likely to develop breast cancer than are African-American women,
but among women under the age of 50, African-American women are at higher
risk.
-
Gender: Breast cancer
in men accounts for less than 1% of the overall number of breast cancer
cases. However, men should be aware of risk factors in their family history
and of signs and symptoms of the disease just like women.
|
 |
-
Genetics: Although family
history has long been considered a risk factor for breast cancer, it is
now estimated that only about 5%-10% of breast cancers are considered the
result of genetic predisposition. The two breast cancer “susceptibility”
genes—BRCA1 and BRCA2—which were discovered in 1994 are estimated to account
for 40%-50% of all such cases of hereditary breast cancers.
-
Family history: The primary
risk associated with a family history of breast cancer is when there is
a “first-degree” relative who has developed the disease – a mother, sister,
or daughter. This is especially significant when the individual developed
cancer at an early age. Risk is also considered higher for women who have
other relatives with the disease, but the risk is not considered as high.
Many authorities attribute this risk to similarities in lifestyle combined
with a potential familial trait.
-
Personal history of breast
cancer: A woman who has had breast cancer is at a higher risk for both
a recurrence of the original disease and for a new breast cancer than the
overall population.
-
History of benign breast
changes with clinical diagnosis of atypical hyperplasia: For many years
it was thought that a woman with benign breast change was at a higher risk
of breast cancer. However, many believe that the risk was more related
to a higher difficulty of detecting a change in breast tissue than to a
genuinely higher risk. Currently, the increased risk is considered to affect
those women who have a clinical diagnosis of atypical hyperplasia only.
-
Hormonal factors: Breast
tissue is affected by a woman’s hormones throughout her reproductive years.
And the usual criteria for assessing a higher level of risk for breast
cancer are: early onset of menstruation, late onset of menopause, older
age at giving birth, and a small number of pregnancies.
The National Cancer Institute
and the National Surgical Adjuvant Breast and Bowel Project (NSABP)
Biostatistics Center have developed a web-based tool called the Breast
Cancer Risk Assessment Tool designed for health care professionals to calculate
a patient's risk of developing breast cancer in the next five years and
also over the patient's lifetime. Find
out more.
The Study
of Tamoxifen and Raloxifene (STAR), one of the largest breast cancer
prevention studies ever conducted, is currently recruiting volunteers at
more than 400 centers in the United States, Puerto Rico, and Canada. Learn
more about the STAR Trial from the National Cancer Institute.

|